A VigiBase Descriptive Study of Fidaxomicin Adverse Events

被引:0
|
作者
Khan, Mohd [1 ]
Jaser, Nehad [1 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Clin Pharm Dept, Al Kharj, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2023年 / 42卷 / 09期
关键词
adverse event; fidaxomicin; macrolides; VigiBase; CLOSTRIDIUM-DIFFICILE; FOOD;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
. Fidaxomicin is a macrocyclic antibiotic used for the treatment of Clostridium difficile infection in adults. Fidaxomicin's most frequent side effects included nausea, vomiting, abdominal pain, gastrointestinal bleeding, and anemia. The present descriptive study that was conducted to describe the most reported adverse events of fidaxomicin using VigiBase. During the study period, 1289 reports were submitted to the World Health Organization. The most reported events were general disorders and administration site conditions (29%), infections and infestations (16%), gastrointestinal disorders (16%), and injury, poisoning, and procedural complications (9%). It is necessary to continue and systematically monitor the safety of fidaxomicin to optimize the management of Clostridium difficile infection.
引用
收藏
页码:1856 / 1859
页数:4
相关论文
共 50 条
  • [21] Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines
    Dutta, Siddhartha
    Kaur, Rimplejeet
    Charan, Jaykaran
    Bhardwaj, Pankaj
    Ambwani, Sneha R.
    Babu, Shoban
    Goyal, Jagdish P.
    Haque, Mainul
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [22] Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
    Zhang, Qingxia
    Ding, Qian
    Yan, Suying
    Yue, Qun-Ying
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (09) : 1521 - 1526
  • [23] Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
    Qingxia Zhang
    Qian Ding
    Suying Yan
    Qun-Ying Yue
    European Journal of Clinical Pharmacology, 2022, 78 : 1521 - 1526
  • [24] Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
    Montastruc, Jean-Louis
    Rousseau, Vanessa
    Durrieu, Genevieve
    Bagheri, Haleh
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1479 - 1480
  • [25] Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
    Jean-Louis Montastruc
    Vanessa Rousseau
    Geneviève Durrieu
    Haleh Bagheri
    European Journal of Clinical Pharmacology, 2020, 76 : 1479 - 1480
  • [26] Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: A descriptive study
    Gerber, A.
    Lopes, A. M. da Silva
    Szuts, N.
    Ribordy-Baudat, V.
    Ebneter, A.
    Perrinjaquet, C.
    Betticher, D.
    Cote, M.
    Duchosal, M. A.
    Brennan, C.
    Decosterd, S.
    Peters, S.
    Koelliker, R.
    Ninane, F.
    Jeitziner, M-M.
    Colomer-Lahiguera, S.
    Dietrich, P-Y.
    Simon, M.
    Gaignard, M-E.
    Eicher, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 825 - 825
  • [27] A Descriptive Study of Adverse Events from Clenbuterol Misuse and Abuse for Weight Loss and Bodybuilding
    Spiller, Henry A.
    James, Kyla J.
    Scholzen, Steven
    Borys, Douglas J.
    SUBSTANCE ABUSE, 2013, 34 (03) : 306 - 312
  • [28] Adverse events of emergency surgical front of neck airway access: an observational descriptive study
    Okada, Asami
    Okada, Yohei
    Kandori, Kenji
    Ishii, Wataru
    Narumiya, Hiromichi
    Iizuka, Ryoji
    ACUTE MEDICINE & SURGERY, 2022, 9 (01):
  • [29] A VigiBase Descriptive Study of Fluoroquinolone-Associated Peripheral Nervous System Disorders
    Huruba, Madalina
    Farcas, Andreea
    Leucuta, Daniel Corneliu
    Bucsa, Camelia
    Mogosan, Cristina
    PHARMACEUTICALS, 2022, 15 (02)
  • [30] Adverse events reported in the context of the use of cannabis or cannabinoid derivatives: exploration of data recorded in Vigibase
    Jouanjus, Emilie
    Deguilhem, Amelia
    Merad, Sonia
    Lapeyre-Mestre, Maryse
    THERAPIE, 2021, 76 (02): : 180 - 181